Literature DB >> 28070006

Susceptibility to Miltefosine in Brazilian Clinical Isolates of Leishmania (Viannia) braziliensis.

Caroline R Espada1, Fatima Ribeiro-Dias2, Miriam L Dorta2, Ledice Inácia de Araújo Pereira2, Edgar M de Carvalho3,4, Paulo R Machado4, Albert Schriefer4, Jenicer K U Yokoyama-Yasunaka1, Adriano C Coelho1,5, Silvia R B Uliana1.   

Abstract

Leishmania (Viannia) braziliensis is the main causative species of tegumentary leishmaniasis in Brazil. In this study, we evaluated the susceptibility of 16 clinical isolates of L. (V.) braziliensis from different regions of Brazil to miltefosine in vitro. Half-maximal inhibitory concentrations of miltefosine varied from 22.9 to 144.2 μM against promastigotes and from 0.3 to 4.2 μM against intracellular amastigotes. No significant differences were found between isolates of different geographical origins. A clear correlation between the EC50 against promastigotes and amastigotes within each isolate was found. These findings contribute to the evaluation of miltefosine's potential and limitations for the treatment of tegumentary leishmaniasis in Brazil.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28070006      PMCID： PMC5361541          DOI： 10.4269/ajtmh.16-0811

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN： 0002-9637            Impact factor:   2.345


  18 in total

1.  Treatment of Bolivian mucosal leishmaniasis with miltefosine.

Authors:  J Soto; J Toledo; L Valda; M Balderrama; I Rea; R Parra; J Ardiles; P Soto; A Gomez; F Molleda; C Fuentelsaz; G Anders; H Sindermann; J Engel; J Berman
Journal:  Clin Infect Dis       Date:  2006-12-27       Impact factor: 9.079

2.  In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.

Authors:  Dhiraj Kumar; Arpita Kulshrestha; Ruchi Singh; Poonam Salotra
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

3.  In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis.

Authors:  Vijay Kumar Prajapati; Smriti Sharma; Madhukar Rai; Bart Ostyn; Poonam Salotra; Manu Vanaerschot; Jean-Claude Dujardin; Shyam Sundar
Journal:  Am J Trop Med Hyg       Date:  2013-08-26       Impact factor: 2.345

Review 4.  Treatment of New World cutaneous leishmaniasis with miltefosine.

Authors:  J Soto; J Berman
Journal:  Trans R Soc Trop Med Hyg       Date:  2006-08-22       Impact factor: 2.184

5.  Three new sensitive and specific heat-shock protein 70 PCRs for global Leishmania species identification.

Authors:  A M Montalvo; J Fraga; I Maes; J-C Dujardin; G Van der Auwera
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-15       Impact factor: 3.267

6.  Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.

Authors:  Anette Chrusciak-Talhari; Reynaldo Dietze; Carolina Chrusciak Talhari; Roberto Moreira da Silva; Ellen Priscila Gadelha Yamashita; Gerson de Oliveira Penna; Paulo Roberto Lima Machado; Sinésio Talhari
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

7.  Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.

Authors:  Luisa Consuelo Rubiano; María Consuelo Miranda; Sandra Muvdi Arenas; Luz Mery Montero; Isabel Rodríguez-Barraquer; Daniel Garcerant; Martín Prager; Lyda Osorio; Maria Ximena Rojas; Mauricio Pérez; Ruben Santiago Nicholls; Nancy Gore Saravia
Journal:  J Infect Dis       Date:  2012-01-11       Impact factor: 5.226

8.  In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B.

Authors:  Rogéria C Zauli-Nascimento; Danilo C Miguel; Jenicer K U Yokoyama-Yasunaka; Ledice I A Pereira; Milton A Pelli de Oliveira; Fátima Ribeiro-Dias; Miriam L Dorta; Silvia R B Uliana
Journal:  Trop Med Int Health       Date:  2009-10-26       Impact factor: 2.622

9.  In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis--status of newly introduced drugs.

Authors:  Vijay Kumar Prajapati; Sanjana Mehrotra; Shalini Gautam; Madhukar Rai; Shyam Sundar
Journal:  Am J Trop Med Hyg       Date:  2012-08-27       Impact factor: 2.345

10.  Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial.

Authors:  Paulo R Machado; Julia Ampuero; Luiz H Guimarães; Leonardo Villasboas; Ana T Rocha; Albert Schriefer; Rosana S Sousa; Anette Talhari; Gerson Penna; Edgar M Carvalho
Journal:  PLoS Negl Trop Dis       Date:  2010-12-21
View more
  4 in total

1.  Virtual screening to identify Leishmania braziliensis N-myristoyltransferase inhibitors: pharmacophore models, docking, and molecular dynamics.

Authors:  Juliana Cecília de Carvalho Gallo; Larissa de Mattos Oliveira; Janay Stefany Carneiro Araújo; Isis Bugia Santana; Manoelito Coelho Dos Santos Junior
Journal:  J Mol Model       Date:  2018-08-29       Impact factor: 1.810

2.  Isolation, typing, and drug susceptibility of Leishmania (Leishmania) infantum isolates from dogs of the municipality of Embu das Artes, an endemic region for canine leishmaniasis in Brazil.

Authors:  Bianca A Ferreira; Thaynan F C Martins; Elizabeth M Coser; Viviane da L Oliveira; Edite H Yamashiro-Kanashiro; Mussya C Rocha; Marcelo M Pinto; Paulo C Cotrim; Adriano C Coelho
Journal:  Parasitol Res       Date:  2022-07-08       Impact factor: 2.383

3.  Investigation of the pathways related to intrinsic miltefosine tolerance in Leishmania (Viannia) braziliensis clinical isolates reveals differences in drug uptake.

Authors:  Caroline R Espada; Rubens M Magalhães; Mario C Cruz; Paulo R Machado; Albert Schriefer; Edgar M Carvalho; Valentín Hornillos; João M Alves; Angela K Cruz; Adriano C Coelho; Silvia R B Uliana
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-02-25       Impact factor: 4.077

4.  Activity of paromomycin against Leishmania amazonensis: Direct correlation between susceptibility in vitro and the treatment outcome in vivo.

Authors:  Elizabeth M Coser; Bianca A Ferreira; Nilson Branco; Edite H Yamashiro-Kanashiro; José Angelo L Lindoso; Adriano C Coelho
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2020-08-15       Impact factor: 4.077
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.